NAD+ for Sale USA: State Lines Bind the Clinic, Not the Vial

Search NAD+ for sale USA and most of what comes back is a shipping claim dressed up as a quality claim. Domestic stock is genuinely worth something, and it is worth being precise about what, because the phrase gets asked to carry far more weight than it can hold.

What it buys is short transit, a customs step that never happens, a return address you could physically go to, and a dispute that stays inside one legal system. The supplier we link holds US stock and dispatches same day before 2pm CST, which on a $52.00 gram of NAD+ after the code PEPTIDEDECK is most of the practical difference between a good order and a bad one.

What it does not buy is any change to the material. Grade, testing scope and endotoxin status are set by whoever manufactured and handled the powder, and a warehouse in Texas can hold exactly the same batch a warehouse in Shenzhen would have shipped. Nothing about a domestic label answers the question FDA raised about this compound, which we get to below.

We earn a commission on the link, as our affiliate disclosure explains. It is also why this page separates the shipping argument from the quality argument instead of letting the first one do the work of the second.

Cold chain is the argument usually made for buying domestically, and on NAD+ it deserves a more careful answer than it normally gets. Lyophilized powder is the stable form of most of these compounds. It is not a refrigerated liquid in transit, and a few days at ambient temperature is a different proposition from a few weeks.

The difference domestic stock makes is therefore about the tail of the distribution rather than the average. A domestic parcel arrives in days, in a known climate, with a tracking number that resolves. An international one can sit in a facility for an indeterminate stretch, and July in a transit hub is not a controlled environment. You cannot see any of that from the outside, and the vial that arrives looks identical either way.

Once it reaches you, storage is your problem entirely, and it is the part people underestimate on a gram. A single 1,000 mg vial is not a one-evening purchase, so it will be in your possession for a while, and how you keep it matters more than how it travelled. We do not publish handling protocols here. PeptideDosage covers the arithmetic and the storage question at its NAD+ page.

FDA is direct about personal imports, and the wording is stronger than most people expect. On its personal importation page, the agency states that in most circumstances it is illegal for individuals to import drugs or devices into the U.S. for personal use, because products purchased from other countries often have not been approved by FDA for use and sale here.

There is a narrow set of situations in which FDA personnel may consider a more permissive decision, and it is worth reading rather than assuming. It covers products not for the treatment of a serious condition with no known significant health risk, and prescription products for a serious condition where no effective domestic treatment is available, the product is not being commercialized to U.S. residents, the quantity is generally no more than a three month supply, and you can name the U.S.-licensed doctor responsible for your treatment. That is a policy written for a patient continuing a therapy, not for a research-supply order.

The same page lists when FDA would refuse a personal importation: a product on an import alert, a shipment that appears intended for commercial distribution, one that appears to present a serious risk to health, or an FDA-regulated article that appears to represent health fraud.

What that means in practice is unglamorous. An intercepted parcel usually produces a notice rather than a knock at the door, and the loss is the money. There is no insurer, no chargeback guarantee unless your vendor has a written policy and honours it, and no arbitration. Buying inside the country removes that entire category of failure, which is the strongest single argument for a domestic listing and one worth more than any of the marketing around it.

Here is where NAD+ diverges from the compounds this site usually covers, and it is the most useful thing on this page. NAD+ has a real clinic channel in the United States, and that channel is governed state by state in a way a mail-order parcel simply is not.

Administering an infusion is the practice of medicine and nursing, and both are licensed at state level. Whether a nurse can run a drip under standing orders, what supervision a clinic needs, what a medical spa is allowed to do without a physician on site, and how aggressively a board enforces any of it varies across the country. That is why an identical drip bar concept looks legal in one state and draws a board complaint in another.

The compounding half is split. Under section 503A, compounding is done by state-licensed pharmacies and physicians, and the state board of pharmacy is the nearest regulator. Under section 503B, outsourcing facilities register with FDA directly, and FDA publishes a list of registered outsourcing facilities you can check by name. If a clinic tells you its NAD+ comes from an outsourcing facility, that claim is verifiable in about a minute.

None of that machinery touches a research-supply order. There is no state licence involved, no board with jurisdiction over the seller, and no professional standing to revoke. That is the honest trade the vial route makes: it escapes the patchwork, and it escapes the protection at the same time.

So the state question is worth asking about the clinic and is nearly meaningless about the vendor. If you are choosing between a local infusion and a mail order, that asymmetry is the actual difference, and it is more informative than any comparison of shipping speeds.

It is easy to read compounding regulation as bureaucracy until you know what produced it. FDA states the case in one line on its own compounding information for states page: in 2012, contaminated drugs compounded by a Massachusetts pharmacy led to more than 750 cases of infection and more than 60 deaths of patients in 20 states.

That is the event behind the 503A and 503B framework, and it is the reason the grade of a bulk substance is not a paperwork question. Contamination in a sterile preparation is not a quality inconvenience, it is the failure mode.

Which brings the argument back to NAD+ specifically. In a compounding notice with content current as of 10/30/2024, FDA wrote that it is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products, that food-grade ingredients are not suitable for compounding sterile drugs without appropriate processing because of the high risk of contamination with microbes and endotoxins, and that it has received adverse event reports after use of NAD+ injectable drugs including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive endotoxin levels.

Read that with the phrase NAD+ for sale USA in mind. Those repackagers were domestic. Those compounders were domestic. The adverse events were domestic. A US shipping origin was true of the entire chain FDA was writing about, which is the clearest possible demonstration that domestic is a logistics fact and not a safety credential.

Treat the claim as a claim. There are four cheap ways to test it and none of them require any expertise.

First, ask where the order ships from before you pay, and get the answer in writing. Second, look at the tracking number when it is issued and confirm the origin scan is where the site said it would be, not a foreign hub with a domestic label applied later. Third, check the return address on the parcel against the address on the website. Fourth, ask what happens if you need to send something back, because a genuine domestic operation has a domestic returns path and a drop-shipper usually does not.

Then separate that entirely from the material question, because they are not related. Ask whether the NAD+ is pharmaceutical grade or food grade, and whether the certificate of analysis for your batch reports an endotoxin result, usually labelled LAL or bacterial endotoxins, rather than identity and purity alone. Those are the two sentences that carry more weight than every logistics claim on the page combined.

The listing we link states that two independent laboratories test every batch, which is more than this market usually publishes, and it holds domestic stock with same-day dispatch before 2pm CST. We have not been shown an endotoxin figure for the NAD+ batches specifically, so we are not going to imply one exists. Ask for it before you order. Our NAD+ buying checklist covers what else belongs on a certificate, and our source-vetting guide applies the same standard across the wider market.

For a reader in the United States there are three routes, and it is worth being blunt about which one you are actually choosing between.

A local clinic gives you a compounded preparation, a professional in the room and a state board that can hear a complaint, at a price NPR put at $200 to upwards of $1,000 for a single drip session. A telehealth or clinic route to a compounded prescription exists because NAD sits in FDA's 503A category 1, which means non-enforcement while the substance is under evaluation, not approval. A research vial gives you $52.00, a paper trail you can read, and nobody watching.

The domestic question is only decisive in one of those comparisons, which is the third one against an overseas equivalent. There, it is decisive: shorter transit, no customs exposure, a real return path, and a dispute that stays in one jurisdiction. Against a clinic, shipping origin is not the variable that should decide anything.

What should decide it is the same thing on every page in this cluster. Ask which grade the material is, ask whether anybody tested it for endotoxins, and hold both the drip bar and the warehouse to the answer. If neither can produce it, the difference between them is $500 and a chair.